NasdaqCM - Nasdaq Real Time Price USD

Windtree Therapeutics, Inc. (WINT)

0.7899

-0.0381

(-4.60%)

At close: May 19 at 4:00:01 PM EDT

0.7900

+0.00

+(0.01%)

After hours: May 19 at 7:20:17 PM EDT

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

Cardiogenic shock is a medically urgent condition and drug treatment innovation is desired by providers who treat the conditionWARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced istaroxime data from the early cardiogenic shock SEISMiC Extensi

GlobeNewswire 14 hours ago

WINT
-4.60%

WINTW
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. “The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to b

GlobeNewswire 3 days ago

WINT
-4.60%

WINTW
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusionWARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases,

GlobeNewswire 7 days ago

WINT
-4.60%

WINTW
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned initial indication in cardiogenic shockWARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovati

GlobeNewswire 13 days ago

WINT
-4.60%

WINTW
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

Initial transaction provides the right to buy the target asset which may provide consistent revenue to Windtree while it continues to develop its biotech pipeline drug candidatesWARRINGTON, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that i

GlobeNewswire 18 days ago

WINT
-4.60%

WINTW
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. “The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogeni

GlobeNewswire last month

EVFM

WINT
-4.60%

WINTW
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse. It prevents pregnancy by maintaining the normal vaginal biome

PR Newswire last month

EVFM

WINT
-4.60%

WINTW
Evofem Reports Fourth Consecutive Year of Net Sales Growth

Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include:

PR Newswire last month

EVFM

WINT
-4.60%

WINTW
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2

GlobeNewswire last month

WINT
-4.60%

WINTW
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Transaction is part of the Company’s new corporate strategy to become a revenue generating biotechWARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partn

GlobeNewswire last month

WINT
-4.60%

WINTW

EVFM
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage

By M. Marin NASDAQ:WINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company developing therapies for a range of cardiovascular and oncology treatments characterized by significant unmet need. The company’s lead indication area is cardiogenic shock (which

Zacks Small Cap Research 2 months ago

WINTW
Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

WARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. application number 18/150,870 directed to “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.”

GlobeNewswire 2 months ago

WINT
-4.60%

WINTW
Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

WARRINGTON, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announced today that the Company has filed a national phase patent application with the Indian patent office claiming priority to PCT/US2024/058923 entitled, “ISTAROXIME AND DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIA

GlobeNewswire 2 months ago

WINT
-4.60%

WINTW
Windtree Therapeutics, Inc. Announces Reverse Stock Split

WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February

GlobeNewswire 2 months ago

WINT
-4.60%

WINTW
Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference

WARRINGTON, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announced that an istaroxime presentation featuring the positive Phase 2b SEISMiC study was given on February 11, 2025 at the Technology and Heart Failure Therapeutics Conference in Boston, MA. Matteo Pagnesi, MD, PhD a cardiologist from Spedali Ci

GlobeNewswire 3 months ago

WINT
-4.60%

WINTW
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline

The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidateWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C (aPKCi) and their use in treating hedgehog pathway-dependent cancers.” Th

GlobeNewswire 4 months ago

WINT
-4.60%

WINTW
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors (“Board”). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served

GlobeNewswire 4 months ago

WINT
-4.60%

WINTW
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder ValueWARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisit

GlobeNewswire 4 months ago

WINT
-4.60%

WINTW
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference

WARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic

GlobeNewswire 4 months ago

WINT
-4.60%

WINTW
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.” The patent filing expands upon data obtained from animal model

GlobeNewswire 5 months ago

WINT
-4.60%

WINTW

Performance Overview

Return	WINT	S&P 500 (^GSPC)
YTD	-95.49%	+1.39%
1-Year	-99.65%	+12.45%
3-Year	-100.00%	+52.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Windtree Therapeutics, Inc. (WINT)

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage

Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

Windtree Therapeutics, Inc. Announces Reverse Stock Split

Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Performance Overview